On July 7, 2026, a new trial update was recorded for a study involving secretin injection, marketed as Chirostim. The study is titled "A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects," registered under NCT07285863.
The trial is listed as Phase 4 and its current status is recruiting. According to the registry entry, the study is designed to examine pancreatic fluid composition in healthy subjects following administration of secretin injection.
No outcome data, efficacy findings, or safety results have been reported for this study at this stage. The listing reflects only the recruiting status and phase classification as posted on the trial registry. Further information, including enrollment criteria and study design details, can be found through the official registry listing linked with this update.
This report reflects the trial's status as of the date noted and does not represent completed results or conclusions. Readers interested in additional background on secretin, including its approved uses and regulatory status, can consult the compound overview for further context.